Canagliflozin to reduce inflammation in heart artery disease
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have stable coronary artery disease (heart attack was more than 60 days ago)
- Have diabetes
- Be able to give informed consent
- Heart pumping function is not severely reduced (EF is 50% or higher)
- Kidney function must be adequate (GFR is 50 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
This trial tests a medicine called dapagliflozin to see if it can reduce chest pain in people whose heart arteries are not blocked but still have reduced blood flow to the heart muscle. It may help improve symptoms and quality of life.
This trial tests whether an SGLT2 inhibitor (a type of diabetes medication) can help reduce stiffness in the arteries of veterans who have obesity. If you are a veteran aged 30-60 with a BMI of 30-45 and have stiffer arteries than expected for your age, this study might be an option.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.